Search filters

Authors whose works are in public domain in at least one jurisdiction

List of works by Andriy Krendyukov

Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies

scientific article published on 02 September 2019

Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study).

scientific article published on 6 November 2016

Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study

scientific article published on 04 March 2019

Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer.

scientific article published on 20 September 2017

Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.

scientific article published on 8 December 2017

Correction to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained

scientific article published on 01 April 2018

Critical Factors Shaping Strategy Development of an Innovative Medicine in Oncology

scientific article published on 01 April 2020

Development and 10-year history of a biosimilar: the example of Binocrit®.

scientific article published on 17 April 2018

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.

scientific article published on 7 February 2018

Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?

scientific article

Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols

scientific article published on 27 March 2019

Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients

article published in 2017

Evolving Communication with Healthcare Professionals in the Pharmaceutical Space: Current Trends and Future Perspectives

scientific article published on 15 June 2020

Extrapolation concept at work with biosimilar: a decade of experience in oncology.

scientific article

Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim

scientific article published on 01 December 2019

Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinati

scientific article published on 24 September 2018

Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma

scientific article published on 03 September 2019

HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience.

scientific article published on 18 December 2017

Innovative oncology products: time to revisit the strategy development?

scientific article published on 25 October 2019

Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study

scholarly article

Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients

scientific article published on 02 November 2019

MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.

scientific article published on 24 November 2017

Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancer

scientific article published on 22 May 2019

Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (  72 h): findings from the MONITOR-GCSF study

scientific article published on 20 October 2018

Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study

scientific article

Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support

scientific article published on 01 September 2018

Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.

scientific article published in September 2017

Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study

scientific article published on 05 March 2019

Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study).

scientific article

Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.

scientific article

Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies

scientific article published on 9 January 2018

Safety analysis of proposed pegfilgrastim biosimilar in Phase I and Phase III studies

scientific article published on 05 March 2019

Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelos

scientific article published on 28 October 2017

The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information.

scientific article published on 17 August 2017

The evolution of value with filgrastim in oncology

scientific article published on 05 March 2019

Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF study

scientific article published on 10 April 2019

Paulina is supported by:

About Paulina

Help